Literature DB >> 3533131

Lack of pharmacokinetic interaction between cholestyramine and acipimox, a new lipid lowering drug.

C de Paolis, R Farina, E Pianezzola, G Valzelli, F Celotti, A E Pontiroli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3533131      PMCID： PMC1401163          DOI： 10.1111/j.1365-2125.1986.tb02926.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  8 in total

1.  The interaction between cholestyramine and drugs.

Authors:  D G Gallo; K R Bailey; A L Sheffner
Journal:  Proc Soc Exp Biol Med       Date:  1965-10

2.  Lack of pharmacokinetic interaction of colestipol and fenofibrate in volunteers.

Authors:  C Harvengt; J P Desager
Journal:  Eur J Clin Pharmacol       Date:  1980-06       Impact factor: 2.953

3.  The effect of colestipol hydrochloride on the bioavailability and pharmacokinetics of clofibrate.

Authors:  K A DeSante; A R DiSanto; K S Albert; D J Weber; R D Welch; T J Vecchio
Journal:  J Clin Pharmacol       Date:  1979 Nov-Dec       Impact factor: 3.126

4.  Radioimmunoassay of acipimox in human plasma and urine.

Authors:  E Maggi; E Pianezzola; G Valzelli
Journal:  Pharmacol Res Commun       Date:  1984-11

5.  Colestipol plus nicotinic acid in treatment of heterozygous familial hypercholesterolaemia.

Authors:  D R Illingworth; B E Phillipson; J H Rapp; W E Connor
Journal:  Lancet       Date:  1981-02-07       Impact factor: 79.321

6.  Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent.

Authors:  L Musatti; E Maggi; E Moro; G Valzelli; V Tamassia
Journal:  J Int Med Res       Date:  1981       Impact factor: 1.671

7.  Reduced triglyceridemia and increased high density lipoprotein cholesterol levels after treatment with acipimox, a new inhibitor of lipolysis.

Authors:  C R Sirtori; G Gianfranceschi; M Sirtori; F Bernini; G Descovich; U Montaguti; L M Fuccella; L Musatti
Journal:  Atherosclerosis       Date:  1981 Feb-Mar       Impact factor: 5.162

8.  Effects of acipimox, a nicotinic acid derivative, on lipolysis in human adipose tissue and on cholesterol synthesis in human jejunal mucosa.

Authors:  C Stirling; M McAleer; J P Reckless; R R Campbell; D Mundy; D J Betteridge; K Foster
Journal:  Clin Sci (Lond)       Date:  1985-01       Impact factor: 6.124
  8 in total
  1 in total

1.  Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.

Authors:  J J Series; A Gaw; C Kilday; D K Bedford; A R Lorimer; C J Packard; J Shepherd
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.